Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trialAlassane Dicko, Roly Gosling, Fanta Koïta et al.|The Lancet Infectious Diseases|2016Cited by 98
Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment TrialIngrid Chen, Alassane Dicko, Halimatou Diawara et al.|The Journal of Infectious Diseases|2018Cited by 27
Socio-demographic and genetic risk factors for drug adherence and persistence across 5 common medication classesMattia Cordioli, Andrea Corbetta, Hanna Maria Kariis et al.|Nature Communications|2024Cited by 14
Socio-demographic and genetic risk factors for drug adherence and persistence: a retrospective nationwide and biobank study across 5 medication classes and 1 845 665 individualsMattia Cordioli, Andrea Ganna, Alessandro Corbetta et al.|medRxiv|2023Cited by 4